Scynexis Inc (SCYX): Operating Cash Flow
-$5.28M
Year ended 2025-12-31
-$13.31M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$5.28M | n/m | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | -$24.01M | n/m | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $60.16M | n/m | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | -$79.88M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$54.56M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$49.35M | n/m | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$38.12M | n/m | 2021-03-29, From 2019-01-01 |
| 2018-12-31 | -$28.32M | n/m | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | -$24.56M | n/m | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | -$29.35M | n/m | 2018-03-13, From 2016-01-01 |
| 2015-12-31 | -$24.55M | n/m | 2017-03-13, From 2015-01-01 |
| 2014-12-31 | -$9.47M | n/m | 2017-03-13, From 2014-01-01 |
| 2013-12-31 | -$4.31M | n/a | 2015-03-30, From 2013-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Scynexis Inc (SCYX) | 2025-12-31 | -$5.28M | n/m |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$20.75M | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$1.99M | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $322.0K | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | -$147.78M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | -$369.52M | n/m |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | -$128.51M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | -$177.96M | n/m |
| Celularity Inc (CELU) | 2025-12-31 | -$13.25M | n/m |
Compare SCYX, CASIF, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗